The ESCMID Study Group for Host and Microbiota Interactions (ESGHAMI) is leading the way in bridging diagnostics, clinical research, and scientific studies across the relatively new field of microbiota research in Europe. Together, we seek to understand the clinical significance of host-microbiota associated diseases and health, and explore relevant therapeutic interventions. Our research covers:
Which trial do we need? A sequential multiple assignment randomized trial to determine the optimal Clostridioides difficile treatment sequence.
van Prehn J, van Werkhoven CH, Skinner AM, Guery B, Dubberke ER, Kuijper EJ. Clinical Microbiology and Infection 2024;30(2):165–169.
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection.
van Prehn J, Fitzpatrick F, Kuijper EJ. Lancet Gastroenterol Hepatol. 2022;7(12):1083–1091.
Bacteriophage therapy in humans.
Nir-Paz R, Kuijper EJ. Clin Microbiol Infect. 2023;29(6):679–681.
Update on Microbiota-derived therapies for recurrent Clostridioides difficile infections, 2023.
Benech N, Barbut N, Fitzpatrick F, Krutova M, Davies K, Druart C, Cordaillat-Simmons M, hHeritage J, Guery B, Kuijper E. Clinical Microbiology and Infection. 2023:S1198-743X(23)00597-9.
Faecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma
Update on Live biotherapeutic products and FMT-like treatments for recurrent Clostridioides difficile infections
21 June 2023
Microbiome from benchtop to bedside technical workshop
If you have questions or comments for our study group, we warmly invite you to contact us!